RVPH — Reviva Pharmaceuticals Holdings Cashflow Statement
0.000.00%
Annual cashflow statement for Reviva Pharmaceuticals Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.52 | -24.3 | -39.3 | -29.9 | -19.9 |
| Depreciation | |||||
| Non-Cash Items | -1.44 | 0.371 | 3.65 | 0.913 | 2.14 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.702 | 5.01 | 7.28 | -4.54 | -6.87 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -10.7 | -19 | -28.3 | -33.5 | -24.6 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 31.6 | 7.79 | 33.2 | 23.7 | 25.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.9 | -11.2 | 4.85 | -9.89 | 0.962 |